Search Results - "Coleman, RL"

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial by Holman, Rury R, Coleman, Ruth L, Huo, Yong, Rydén, Lars, Schröder, Stefan, Tendera, Michal, Tucker, Lynne, Tuomilehto, Jaakko, Wei, Yidong, Wang, Duolao, Keenan, Joanne, Milton, Joanne, Standl, Eberhard, Weng, Jianping, MacDonald, Michael, Yan, Xiaowei, Zhang, Yuqing, Bethel, M Angelyn, Xu, Wen, Hearn, Sarah, Su, Shu-Yi, Liyanage, Winitha, Paul, Sanjoy, Batra, Priyanka, Nawalaniec, Olga, Patel, Yash, Bi, Jing, Hu, Rong, Liu, Yang, Zhou, Jing, Peng, Jianjun, Wei, Guanglin, Zhang, Shuyang, Wu, Lirong, Han, Lei, Liao, Ronghong, Ran, Boli, She, Qiang, Pu, Xiaodong, Wang, Yan, Xie, Qiang, Zhou, Wanxing, Zhou, Shuxian, Wu, Chun, Zhang, Aidong, Lai, Shayi, Yang, Jin, Kuang, Riyu, Cao, Xufen, Wang, Li'na, Dong, Pingshuan, Zhang, Shouyan, Liu, Xincan, Gu, Ye, Su, Xi, Wang, Daowen, Guo, Ying, Zhang, Yumin, Man, Ronghai, Bian, Rongwen, Biao, Xu, Jin, Hui, Yu, Jiangyi, Zhang, Hang, Guo, Yan, Lv, Ke, Li, Dongye, Gu, Xiang, Liu, Jun, Zhang, Shuying, Jin, Yuanzhe, Song, Mei, Xue, Li, Gao, Feng, Li, Xiaoyan, Hou, Zishan, Wang, Yanping, Qi, Wenbo, Feng, Bo, Gu, Shuiming, Gu, Mingjun, Guo, Xingui, Jiang, Yifeng, Jin, Huigen, Liu, Qiliang, Lu, Guoping, Miao, Peizhi, Wang, Yuanming, Ma, Jin, Tao, Jianhong, Li, Decai, Jiang, Tiemin, Lin, Jingna, Guo, Xukun, Li, Tong, Zheng, Shaoxiong, Yuan, Zhanjun, Bai, Wenwei, Hao, Yinglu, Tang, Lijiang

“…The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is…”
Get full text

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial by Gerstein, Hertzel C, Coleman, Ruth L, Scott, Charles A B, Xu, Shishi, Tuomilehto, Jaakko, Rydén, Lars, Holman, Rury R

“…We examined the impact of acarbose, an α-glucosidase inhibitor, on incident diabetes and regression to normoglycemia in 6,522 Acarbose Cardiovascular…”
Get full text

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial by Wamil, Malgorzata, McMurray, John J.V., Scott, Charles A.B., Coleman, Ruth L., Sun, Yihong, Standl, Eberhard, Rydén, Lars, Holman, Rury R.

“…•Higher age and plasma creatinine, lower haemoglobin, and HF, MI or AF predicted hHF.•Higher age and creatinine values predicted case fatality.•Acarbose did…”
Get full text

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial by Morrow, Liam Mc, Becker, Frauke, Coleman, Ruth L., Gerstein, Hertzel C., Rydén, Lars, Schöder, Stefan, Gray, Alastair M., Leal, Jose, Holman, Rury R.

“…Background The Acarbose Cardiovascular Evaluation (ACE) trial (ISRCTN91899513) evaluated the alpha‐glucosidase inhibitor acarbose, compared with placebo, in…”
Get full text

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience by Hou, Ming-Mo, Liu, Xiaochun, Wheler, Jennifer, Naing, Aung, Hong, David, Coleman, Robert L, Tsimberidou, Apostolia, Janku, Filip, Zinner, Ralph, Lu, Karen, Kurzrock, Razelle, Fu, Siqing

“…Activated PI3K/AKT/mTOR pathway frequently occurs in metastatic or recurrent cervical carcinomas. However, the clinical benefits of matched therapy, a…”
Get full text

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study by Coleman, Robert L, Sill, Michael W, Lankes, Heather A, Fader, Amanda Nickles, Finkler, Neil J, Hoffman, James S, Rose, Peter G, Sutton, Gregory P, Drescher, Charles W, McMeekin, D. Scott, Hu, Wei, Deavers, Michael, Godwin, Andrew K, Alpaugh, R. Katherine, Sood, Anil K

“…Abstract Objectives Aflibercept targets vascular endothelial growth factor and placental growth factor. We evaluated activity and toxicity of aflibercept in…”
Get full text

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants by Theodorakis, Michael J., Coleman, Ruth L., Feng, Huimei, Chan, Juliana, Chiasson, Jean-Louis, Ge, Junbo, Gerstein, Hertzel C., Huo, Yong, Lang, Zhihui, McMurray, John J., Rydén, Lars, Schröder, Stefan, Tendera, Michal, Tuomilehto, Jaakko, Yang, Wenying, Hu, Dayi, Pan, Changyu, Holman, Rury R.

“…The ACE trial is examining whether acarbose, an insulin-sparing postprandial glucose-lowering agent, can reduce cardiovascular (CV) events in patients who have…”
Get full text

Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes by Stevens, Richard J., Coleman, Ruth L., Adler, Amanda I., Stratton, Irene M., Matthews, David R., Holman, Rury R.

“…Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes UKPDS 66 Richard J. Stevens , PHD , Ruth L. Coleman , BSC ,…”
Get full text

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer by Munkarah, A.R., Coleman, R.L.

“…The optimal strategy for salvage therapy in patients who suffer from ovarian cancer recurrence after a disease-free interval is not established. The objective…”
Get full text

Lymphatic Mapping and Sentinel Node Identification in Patients With Cervix Cancer Undergoing Radical Hysterectomy and Pelvic Lymphadenectomy by Levenback, C.

Get full text

Risk factors for heart failure in the ACE trial population by Scott, CAB, McMurray, JJ, Ryden, L, Sun, Y, Tendera, M, Coleman, RL, Holman, RR

Get full text

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial by Piskorz, A.M, Lin, K.K, Morris, J, Mann, E, Oza, A, Coleman, R.L, O'Malley, D.M, Friedlander, M, Cragun, J.M, Ma, L, Giordano, H, Raponi, M, McNeish, I.A, Swisher, E, Brenton, J.D

“…Background: TP53 mutations are present in >97% cases of high-grade serous ovarian cancer (HGSOC). Detection of TP53 mutations in ctDNA extracted from plasma…”
Get full text

Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer by Lin, K, Tinker, A.V, Kondrashova, O, Ho, G, Wakefield, M, Coleman, R.L, O'Malley, D.M, Floquet, A, Sun, J, Maloney, L, Giordano, H, Harding, T, Raponi, M, McNeish, I.A, Swisher, E, Scott, C.L

“…Background: High-grade ovarian carcinomas (HGOC) with mutated BRCA1, BRCA2, or other core homologous recombination repair (HRR) genes are sensitive to…”
Get full text

Intraoperative Lymphatic Mapping and Sentinel Node Identification with Blue Dye in Patients with Vulvar Cancer by Levenback, Charles, Coleman, Robert L., Burke, Thomas W., Bodurka-Bevers, Diane, Wolf, Judith K., Gershenson, David M.

“…Objective. To determine the effectiveness of intraoperative lymphatic with blue dye alone as a means of localizing sentinel nodes in patients with vulvar…”
Get full text

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults by BARDITCH-CROVO, Patricia, DEEKS, Steven G, MCGOWAN, I. A. N, LIETMAN, Paul S, COLLIER, A. N. N, SAFRIN, Sharon, COAKLEY, Dion F, MILLER, Michael, KEARNEY, Brian P, COLEMAN, Rebecca L, LAMY, Patrick D, KAHN, James O

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers by Coleman, Robert L., Broaddus, Russell R., Bodurka, Diane C., Wolf, Judith K., Burke, Thomas W., Kavanagh, John J., Levenback, Charles F., Gershenson, David M.

“…To evaluate the efficacy and tolerability of imatinib mesylate (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) in patients with recurrent ovarian and…”
Get full text

Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial by SANTOSO, Joseph T, LUCCI, Joseph A, COLEMAN, Robert L, SCHAFER, Ilona, HANNIGAN, Edward V

“…To determine which hydration (saline, saline + mannitol, or saline + furosemide) is associated with least cisplatin nephrotoxicity. We randomized 49 women who…”
Get full text

Effects of a laboratory-based skills curriculum on laparoscopic proficiency: A randomized trial by Coleman, Robert L., Muller, Carolyn Y.

“…Objective: The purpose of this study was to determine the effect and validity of an intensive laboratory-based laparoscopic skills training curriculum on…”
Get full text

Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer by Fujiwara, Keiichi, Markman, Maurie, Morgan, Mark, Coleman, Robert L.

“…Intraperitoneal (IP) chemotherapy is an attractive approach to the treatment of ovarian cancer because the disease remains confined to the peritoneal cavity…”
Get full text

Non-HDL Cholesterol Is Less Informative Than the Total-to-HDL Cholesterol Ratio in Predicting Cardiovascular Risk in Type 2 Diabetes by Holman, Rury R, Coleman, Ruth L, Shine, Brian S.F, Stevens, Richard J

“…Holman et al evaluate whether non-high density lipoprotein (HDL) cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting…”
Get full text